I. Mäkelä
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
I. Mäkelä has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Rogerio Figueiredo
Medical Immune Oncology Research Group (MIORG), Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland
1 shared publication E.‐M. Birkman
Laboratory Division, Department of Pathology, Turku University Hospital University of Turku Turku Finland
1 shared publication- Maria Sundvall
Cancer Research Unit, Institute of Biomedicine, and FICAN West Cancer Center Laboratory, University of Turku, and Turku University Hospital
1 shared publication - Roosa E. Kallionpää
Auria Biobank, University of Turku and Turku University Hospital
1 shared publication - S. A. Koskela
Medical Immuno‐Oncology Research Group, Cancer Research Unit, Institute of Biomedicine, Faculty of Medicine University of Turku Turku Finland
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (4) , e70153
Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune‐Associated Biomarkers of Anti‐ PD1 Response in Metastatic Melanoma
Resistance to anti‐PD1 therapy remains a major challenge in metastatic melanoma, despite long‐term benefit in some patients. Since a functional dendritic cell (DC)‐CD8 + T cell axis is essential for anti‐PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC‐CD8 + T cell axis in melanoma, evaluating their associations with anti‐PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre‐treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker‐associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non‐responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment‐ and site‐specific. Among them, FAM57A , GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45 + immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K‐AKT‐mTORC1/MAPK signalling, especially upon co‐expression. Together, these results identify FAM57A , GSTA4 and KCTD1 as emerging immune‐associated biomarkers linked to established resistance‐associated immune states and poor prognosis in metastatic melanoma.
- 21 October 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (4) , e70153
Open AccessSpatial Transcriptomic and Proteomic Analysis Identifies Novel Immune‐Associated Biomarkers of Anti‐ PD1 Response in Metastatic Melanoma
Resistance to anti‐PD1 therapy remains a major challenge in metastatic melanoma, despite long‐term benefit in some patients. Since a functional dendritic cell (DC)‐CD8 + T cell axis is essential for anti‐PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC‐CD8 + T cell axis in melanoma, evaluating their associations with anti‐PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre‐treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker‐associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non‐responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment‐ and site‐specific. Among them, FAM57A , GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45 + immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K‐AKT‐mTORC1/MAPK signalling, especially upon co‐expression. Together, these results identify FAM57A , GSTA4 and KCTD1 as emerging immune‐associated biomarkers linked to established resistance‐associated immune states and poor prognosis in metastatic melanoma.